MedicineWorld.Org
Your gateway to the world of medicine
Home
News
Cancer News
About Us
Cancer
Health Professionals
Patients and public
Contact Us
Disclaimer

Medicineworld.org: Treating Hypertension Early

Back to heart news Blogs list Cancer blog  


Subscribe To Heart News RSS Feed  RSS content feed What is RSS feed?

Treating Hypertension Early

Treating Hypertension Early
Treating pre-high blood pressure with medicine and lifestyle modifications reduces the risk of patients progressing to hypertension, a new study involving scientists at UT Southwestern Medical Center has concluded.

The findings, appearing in an upcoming issue of The New England Journal of Medicine, are the result of a four-year study of more than 800 patients who had a condition known as pre-hypertension. A blood pressure between 120 and 139 mm Hg systolic and 80 to 89 mm Hg diastolic indicates pre-hypertension.

"The recommended guidelines currently list lifestyle modifications for therapy of pre-hypertension," said Dr. Shawna Nesbitt, associate professor of internal medicine at UT Southwestern and an author on the study. "But the long-term maintenance of a lifestyle change is dismal. Patients typically don't stick to it."

Present guidelines recommend that pre-high blood pressure be managed with changes in the patient's lifestyle through weight loss, salt restriction, exercise and dietary modification. Despite intense efforts to keep patients from developing hypertension, an increasing number of people are diagnosed each year. High blood pressure is one of the leading causes of other cardiovascular ailments, including heart disease and stroke.

Dr. Nesbitt collaborated with scientists at several institutions to find out if therapy with angiotensin-receptor blockers, or ARBs, could prevent the development of hypertension. This is the first human study involving therapy of prehigh blood pressure with an ARB.

"We chose to administer a low dose of the ARB medicine candesartan cilexetil because it has qualities that suggest it changes characteristics of the blood vessel - an effect that may be maintained beyond the period of therapy," Dr. Nesbitt said. "As high blood pressure develops, the walls of the blood vessels actually get thicker, setting the stage for hypertension to propagate. This medicine and others like it seem to decrease that thickness and improve the function of the blood vessels."

In the study, patients between the ages of 30 and 65 with blood pressures between 130 and 139 mm Hg systolic and 85 to 89 mm Hg diastolic were treated over a four-year period with either a placebo or with ARB medications.

"In a previous study, it was shown that over four years, if left untreated, 40 percent of people with prehigh blood pressure become hypertensive," Dr. Nesbitt said.

Half of the participants were given candesartan cilexetil for two years and then were removed from the medicine for two years; the other half of the group was untreated for the four years. Even up to two years after therapy was stopped, the candesartan-treated pre-hypertensive patients had a 15.8 percent lower risk of developing high blood pressure compared with untreated pre-hypertensive patients. Both groups were advised to modify their diet and exercise habits.

"I think this is the tip of the iceberg in the further study of new therapy protocols for pre-hypertension" Dr. Nesbitt said. "We've typically waited until people have high blood pressure before we treated them, and it's really hard to stave off the disease's progression when you treat it later in its development. This is an opportunity for us to investigate early therapys and to see if we can prevent patients from having to be on life-long treatment for hypertension."

The Trial of Preventing Hypertension, or TROPHY, is a four-year, multicenter study, which was investigator-*initiated and financially supported by pharmaceutical company AstraZeneca LP, manufacturer of the candesartan cilexetil drug Atacand.

Dr. Nesbitt is an executive committee member of the TROPHY study. Other authors -- also members of the executive committee -- are from the University of Michigan Medical School, the Medical University of South Carolina, the State University of New York Downstate Medical Center, Rush University Medical Center, Hennepin County Medical Center in Minneapolis, St. Luke's-Roosevelt Hospital Center, and the University of Alabama at Birmingham.



Source: UT Southwestern Medical Center

Posted by: Daniel    Source




Did you know?
Treating pre-high blood pressure with medicine and lifestyle modifications reduces the risk of patients progressing to hypertension, a new study involving scientists at UT Southwestern Medical Center has concluded. The findings, appearing in an upcoming issue of The New England Journal of Medicine, are the result of a four-year study of more than 800 patients who had a condition known as pre-hypertension. A blood pressure between 120 and 139 mm Hg systolic and 80 to 89 mm Hg diastolic indicates pre-hypertension.

Medicineworld.org: Treating Hypertension Early

Aggressive heart therapies still underused| Aspirin might prevent vioxx cardiac damage| Bariatric surgery to control weight in cardiac patients| Black immigrants from africa arrive healthier than those from europe| Exercise stress management gives physiological benefits for heart patients| Heart and cell signaling| Link between obesity inflammation and vascular disease found| Pig hearts in nonhuman primates a success story| Strategies to raise hdl cholesterol levels| Stress test identifies high risk people for coronory heart disease|

Copyright statement
The contents of this web page are protected. Legal action may follow for reproduction of materials without permission.